Yishen Huashi Granules Combined with SGLT-2 Inhibitors in the Treatment of Type 2 Diabetic Nephropathy with Spleen Deficiency and Dampness Excess Syndrome

Key Points

• This research aims to assess the clinical efficacy of combining Yishen Huashi Granules with SGLT-2 inhibitors in treating type 2 diabetic nephropathy.
• Randomly assigned 70 patients with type 2 diabetic nephropathy into control and experimental groups (35 each) between November 2024 and May 2025.
• Control group received SGLT-2 inhibitors; experimental group received Yishen Huashi Granules combined with SGLT-2 inhibitors for 2 months.
• Monitored inflammation factors, kidney function indicators, urinary protein levels, and adverse reactions post-treatment.
• The total effective rate in the experimental group was significantly higher than in the control group (P<0.05).
• Post-treatment, inflammation factors, kidney function indicators, urinary microprotein, and 24-hour total urinary protein decreased in both groups (P<0.05), with the experimental group showing greater reductions (P<0.05).
• No significant difference in adverse reaction rates between groups (P>0.05).